Related Experiment Video
Updated: Dec 13, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Spasticity Management in Persons with Disorders of Consciousness
Bei Zhang1,2, Jay Karri2,3, Katherine O'Brien2
1Department of Physical Medicine and Rehabilitation, McGovern Medical School, University of Texas Health Science Center - Houston, Houston, TX.
Spasticity is common in disorders of consciousness (DoC) patients, often impacting all limbs. Targeted interventions reduced medication needs and improved consciousness levels.
Area of Science:
- Neurology
- Rehabilitation Medicine
- Neuroscience
Background:
- Spasticity is a frequent neurological impairment in patients with disorders of consciousness (DoC).
- Untreated spasticity can hinder environmental interaction and mask subtle signs of consciousness.
- Lack of specific spasticity data in DoC populations may lead to suboptimal treatment.
Purpose of the Study:
- To characterize spasticity in a large DoC rehabilitation program.
- To evaluate the impact of interventions on spasticity and clinical measures in DoC patients.
Main Methods:
- Retrospective chart review of 146 patients admitted to a DoC rehabilitation program.
- Analysis of spasticity characteristics, affected muscle groups, and interventions used.
- Assessment of outcomes related to spasticity management and consciousness levels.
Main Results:
- 95.2% of DoC patients exhibited spasticity, with 52.7% affected in all four limbs.
- Shoulder internal rotators and ankle plantar flexors were most commonly affected.
- Focal interventions (chemodenervation, ITB) were common; systemic medications were reduced by 50%, correlating with improved consciousness.
Conclusions:
- Nearly all DoC patients experience spasticity, often severe.
- Widespread use of focal spasticity interventions facilitated reduction in systemic medications.
- Reduced systemic spasmolytic medication appeared linked to enhanced levels of consciousness.
Related Concept Videos
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
Skeletal Muscle Relaxants: Therapeutic Uses
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

